Regulatory decisions pertaining to aprotinin may be putting patients at risk

CMAJ. 2014 Dec 9;186(18):1379-86. doi: 10.1503/cmaj.131582. Epub 2014 Sep 29.
No abstract available

MeSH terms

  • Antifibrinolytic Agents / therapeutic use*
  • Aprotinin / therapeutic use*
  • Canada
  • Clinical Trials as Topic
  • Drug Approval* / legislation & jurisprudence
  • Humans
  • Risk

Substances

  • Antifibrinolytic Agents
  • Aprotinin